| abstract |
The disclosure relates to crystalline and non-crystalline forms of 3-((3R, 4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl)-3-oxopropionitrile (tofacitinib). The disclosure also relates to pharmaceutical compositions comprising tofacitinib and a penetration enhancer. The penetration enhancer may be oleyl alcohol, linoleyl alcohol, y-linolenyl alcohol, linolenyl alcohol, decyl alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid and arachidic acid, palmitoleic acid, oleic acid, cis-vaccenic acid, linoleic acid, y-linolenic acid, linolenic acid or arachidonic acid. The disclosure also relates to the use of the pharmaceutical compositions in the treatment of disease, such as psoriasis. |